Standardized herbal medicines for the treatment of chronic diseases
| Full text | |
| Author(s): Show less - | 
								
									Fattori, Victor
									
									
									[1]
									
									; 
								
									Zarpelon, Ana C.
									
									
									[1]
									
									; 
								
									Staurengo-Ferrari, Larissa
									
									
									[1]
									
									; 
								
									Borghi, Sergio M.
									
									
									[1]
									
									; 
								
									Zaninelii, Tiago H.
									
									
									[1]
									
									; 
								
									Da Costa, Fernando B.
									
									
									[2]
									
									; 
								
									Aives, Jose C.
									
									
									[3]
									
									; 
								
									Cunha, Thiago M.
									
									
									[3]
									
									; 
								
									Cunha, Fernando Q.
									
									
									[3]
									
									; 
								
									Casagrande, Rubia
									
									
									[4]
									
									; 
								
									Arakawa, Nilton S.
									
									
									[4]
									
									; 
								
									Vern Jr, Waldiceu A.
									
									
									
								
                                 
                                    Total Authors: 12
                                 | 
| Affiliation: | [1] Univ Estadual Londrina, Dept Pathol, Lab Pain Inflammat Neuropathy & Canc, Londrina - Brazil 
									 [2] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, AsterBioChem Res Team, Ribeirao Preto - Brazil 
									 [3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Lab Inflammat & Pain, Ribeirao Preto - Brazil 
									 [4] Univ Estadual Londrina, Ctr Hlth Sci, Dept Pharmaceut Sci, Londrina - Brazil 
									 
                                    Total Affiliations: 4
                                 | 
| Document type: | Journal article | 
| Source: | FRONTIERS IN PHARMACOLOGY; v. 9, SEP 25 2018. | 
| Web of Science Citations: | 3 | 
| Abstract | |
| Background: Gout is the most common inflammatory arthritis worldwide. It is a painful inflammatory disease induced by the deposition of monosodium urate (MSU) crystals in the joints and peri-articular tissues. Sesquiterpene lactones (SLs) are secondary metabolite biosynthesized mainly by species from the family Asteraceae. It has been demonstrated that SLs present anti-inflammatory, analgesic, antitumoral, antiparasitic, and antimicrobial activities. In this study, we aimed at evaluating the efficacy of the SL budlein A in a model of acute gout arthritis in mice. Methods: Experiments were conducted in male Swiss or male LysM-eGFP mice. Animals were treated with budlein A (1 or 10 mg/kg) or vehicle 30 min before stimulus with MSU (100 mu g/10 mu L, intra-articular). Knee joint withdrawal threshold and edema were evaluated using electronic von Frey and caliper, respectively, 1-15 h after MSU injection. Leukocyte recruitment was determined by counting cells (Neubauer chamber), H\&E staining, and using LysM-eGFP mice by confocal microscopy. Inflammasome components, Il-1 beta and Tnf-alpha mRNA expression were determined by RT-qPCR. IL-1 beta and TNF-alpha production (in vitro) and NF-kappa B activation (in vitro and in vivo) were evaluated by ELISA. In vitro analysis using LPS-primed bone marrow-derived macrophages (BMDMs) was performed 5 h after stimulation with MSU crystals. For these experiments, BMDMs were either treated or pre-treated with budlein A at concentrations of 1, 3, or 10 mu g/mL. Results: We demonstrated that budlein A reduced mechanical hypersensitivity and knee joint edema. Moreover, it reduced neutrophil recruitment, phagocytosis of MSU crystals by neutrophils, and Il-1 beta and Tnf-alpha mRNA expression in the knee joint. In vitro, budlein A decreased TNF-alpha production, which might be related to the inhibition of NF-kappa B activation. Furthermore, budlein A also reduced the IL-1 beta maturation, possibly by targeting inflammasome assembly in macrophages. Conclusion: Budlein A reduced pain and inflammation in a model of acute gout arthritis in mice. Therefore, it is likely that molecules with the ability of targeting NF-kappa B activation and inflammasome assembly, such as budlein A, are interesting approaches to treat gout flares. (AU) | |
| FAPESP's process: | 13/08216-2 - CRID - Center for Research in Inflammatory Diseases | 
| Grantee: | Fernando de Queiroz Cunha | 
| Support Opportunities: | Research Grants - Research, Innovation and Dissemination Centers - RIDC | 
| FAPESP's process: | 11/19670-0 - Mechanisms involved in the pathophysiology of rheumatoid arthritis, pain and sepsis | 
| Grantee: | Fernando de Queiroz Cunha | 
| Support Opportunities: | Research Projects - Thematic Grants |